Bristol-Myers Sues to Block Copies of Revlimid, Its Top Seller

Bristol-Myers Squibb’s Celgene unit said Alembic’s proposed generic version of Revlimid infringes seven patents for the blockbuster blood-cancer therapy, Celgene’s top seller.

• Celgene is seeking court orders blocking copies while case proceeds and until patents have expired, and blocking Alembic from making “any solid forms of lenalidomide, compositions or methods claimed” in patents before they’ve expired, according to complaint filed Thursday in federal court in Newark, New Jersey
• Patents cover solid forms of Revlimid’s active ingredient, lenalidomide; compositions containing it; and methods of use and administration of lenalidomide or compositions containing it
• Four patents expire in May 2023, ...